This trial is designed to assess the maximum tolerated dose of two drugs, ribociclib and belinostat, in combination. The trial will start with a dose escalation, followed by an expansion cohort at the identified dose. Dose escalation will be open to patients with triple-negative breast cancer or ovarian cancer. Dose expansion will only be open to patients with triple-negative breast cancer.
- Metastatic Breast Cancer
- Recurrent Ovarian Cancer
1 Primary · 3 Secondary · Reporting Duration: 36 months
Side Effects for
1 Treatment Group
Treatment: all patients
1 of 1
34 Total Participants · 1 Treatment Group
Primary Treatment: Ribociclib · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has there previously been research conducted on Ribociclib?
"Ribociclib was first studied at Azienda Ospedaliera Universitaria Federico II in 2012 and there are currently 58 concluded trials. Of the 55 active studies, many of them take place near Fairfax, Virginia." - Anonymous Online Contributor
In what medical circumstances is Ribociclib typically prescribed?
"Ribociclib is chiefly given to those with refractory peripheral t-cell lymphoma unspecified. It has also proven effective for malignant neoplasms, postmenopause, and relapsed peripheral t-cell lymphoma cases." - Anonymous Online Contributor
How many participants are expected to be recruited for this trial?
"Affirmative, the clinicaltrials.gov records demonstrate that this research is recruiting volunteers at present. The trial was originally posted on May 3rd 2021 and has been updated most recently on May 3rd 2022. 34 subjects are required from 2 sites in total." - Anonymous Online Contributor
Has the Federal Drug Administration certified Ribociclib for therapeutic applications?
"As a phase 1 trial, there is limited data available on the safety and efficacy of ribociclib. Therefore, our team has assigned it a score of 1/3." - Anonymous Online Contributor
Is this trial the inaugural effort of its kind?
"As of now, 55 clinical trials related to Ribociclib are taking place in 447 cities and 48 nations. The first trial commenced eight years ago with the sponsorship of Pfizer and included 189 test subjects. With 58 studies already finished since then, ample data regarding this medication has been amassed." - Anonymous Online Contributor
Are participants currently being enrolled for this medical experiment?
"As per clinicaltrials.gov, this medical study is actively in search of volunteers and was initially established on May 3rd 2021 before being revisited on the same date a year later." - Anonymous Online Contributor